Self-cleaving peptides are key for easy and efficient monoclonal antibody production

September 11, 2015, Agency for Science, Technology and Research (A*STAR), Singapore
Self-cleaving peptides are key for easy and efficient monoclonal antibody production
Efficient, high-quality monoclonal antibody production is made possible through use of self-cleaving peptides. Credit: Sebastian Kaulitzki/Hemera/Thinkstock

Using self-cleaving peptides, A*STAR researchers have designed a vector that improves efficiency for monoclonal antibody production, offering potential for improved preclinical studies.

The production of monoclonal , such as Immunoglobulin G, involves linking large and small polypeptide antibody subunits—heavy and light chain genes. "Balancing the ratio of heavy and light chain expression is essential for high-level and quality antibody expression," explains Yuansheng Yang from the A*STAR Bioprocessing Technology Institute. 

Current industrial methods for producing antibodies, in which light-chain, heavy-chain and selection marker genes are delivered either on separate vectors or a single vector with multiple promoters, are unable to accurately balance light and heavy chain gene expression. This tends to result in many non-expressing cells. 

Using self-cleaving proteins such as 2A peptides, which are commonly derived from viruses, to express the genes seemed a promising alternative to the plasmid vectors favored by industry, "2A peptides enable co-expression of multiple genes at equal amounts by expressing them in one open reading frame," explains Yang. But, while 2A peptides can produce antibodies, incomplete cleavage of 2A can result in the formation of incorrect antibodies that cannot be properly folded and form high molecular aggregates.

Recognizing the potential of these species for monoclonal antibody production, Yang and the team searched for 2A peptides with higher cleavage efficiencies and then developed purification methods to remove incorrect antibody species in instances of incomplete 2A peptide cleavage.

The researchers compared four 2A peptides, both in the presence and absence of glycine-serine-glycine linkers, used to express three bio-similar Immunoglobulin G 1 in Chinese hamster ovary cell lines via transient and stable transfections. 

They found that the inclusion of the glycine-serine-glycine linkers significantly enhanced the cleavage efficiency and the monoclonal antibody expression level for each 2A peptide. T2A, the 2A peptide derived from the Thosea asigna virus, with the gylcine-serine-glycine linker had the highest cleavage efficiency, and when combined with Furin (Furin-GSG-T2A) was most effective for IgG antibody expression.

Although more cleavage efficient, 2A with the glycine-serine-glycine linkers still had some degree of incomplete , resulting in incorrect antibodies. The team tried to remedy this with a purification method they had previously developed, the chromatin-directed clarification. "We expected the removal of incorrect species in the high molecular aggregates," Yang says. "The removal of the incorrect species contained in the IgG monomer, however, was very surprising as there is only a few amino acids difference between that and the correct antibody."

Explore further: Macrophages target tumor cells following monoclonal antibody therapy

More information: "Cleavage efficient 2A peptides for high level monoclonal antibody expression in CHO cells." mAbs 7, 403–412 (2015). www.tandfonline.com/doi/abs/10 … 1008351#.VezuAvmqpBc

Related Stories

Macrophages target tumor cells following monoclonal antibody therapy

January 16, 2014
Monoclonal antibodies directed against tumor antigens have proven effective for treating some forms of cancer. Despite the increasing use of monoclonal antibody therapy, it is not clear how these antibodies drive tumor removal.

Sugar antigen lost its resistance

July 31, 2015
Immunotherapy using monoclonal antibodies is a promising treatment strategy, and it might now be within reach: American scientists have successfully prepared an oligosaccharide enterobacterial antigen for which a monoclonal ...

Study could lead to vaccines and treatment for dengue virus

July 2, 2015
Researchers at Vanderbilt University and the National University of Singapore have determined the structure of a human monoclonal antibody which, in an animal model, strongly neutralizes a type of the potentially lethal dengue ...

Recommended for you

Single-cell study in a childhood brain tumor affirms the importance of context

April 20, 2018
In defining the cellular context of diffuse midline gliomas, researchers find the cells fueling their growth and suggest a potential approach to treating them: forcing their cells to be more mature.

Aggressive breast cancer already has resistant tumour cells prior to chemotherapy

April 20, 2018
Difficult to treat and aggressive "triple-negative" breast cancer is chemoresistant even before chemotherapy begins, a new study by researchers from Karolinska Institutet and the University of Texas MD Anderson Cancer Center ...

Mechanism that drives development of liver cancer brought on by non-alcoholic fatty liver disease discovered

April 19, 2018
A team of researchers from several institutions in China has found a mechanism that appears to drive the development of a type of liver cancer not caused by alcohol consumption. In their paper published in the journal Science ...

Discovery adds to evidence that some children are predisposed to develop leukemia

April 19, 2018
St. Jude Children's Research Hospital researchers have made a discovery that expands the list of genes to include when screening individuals for possible increased susceptibility to childhood leukemia. The finding is reported ...

Scientists identify 170 potential lung cancer drug targets using unique cellular library

April 19, 2018
After testing more than 200,000 chemical compounds, UT Southwestern's Simmons Cancer Center researchers have identified 170 chemicals that are potential candidates for development into drug therapies for lung cancer.

Chip-based blood test for multiple myeloma could make bone biopsies a relic of the past

April 19, 2018
The diagnosis and treatment of multiple myeloma, a cancer affecting plasma cells, traditionally forces patients to suffer through a painful bone biopsy. During that procedure, doctors insert a bone-biopsy needle through an ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.